FDA — authorised 27 August 2018
- Marketing authorisation holder: TETRAPHASE PHARMS
- Status: approved
🇺🇸 Xerava in United States
FDA authorised Xerava on 27 August 2018
Marketing authorisations
FDA — authorised 27 August 2018
- Application: NDA211109
- Marketing authorisation holder: TETRAPHASE PHARMS
- Local brand name: XERAVA
- Indication: POWDER — INTRAVENOUS
- Status: approved
Xerava in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Infectious Disease approved in United States
Frequently asked questions
Is Xerava approved in United States?
Yes. FDA authorised it on 27 August 2018; FDA authorised it on 27 August 2018.
Who is the marketing authorisation holder for Xerava in United States?
TETRAPHASE PHARMS holds the US marketing authorisation.